Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
Authors:
- Guru SonpavdeGSGuru Sonpavde
- Toni K. ChoueiriTCToni K. Choueiri
- Bernard EscudierBEBernard Escudier
- Vincenzo FicarraVFVincenzo Ficarra
- Thomas E. HutsonTHThomas E. Hutson
- Peter F. MuldersPMPeter F. Mulders
- Jean-Jacques PatardJPJean-Jacques Patard
- Brian I. RiniBRBrian I. Rini
- Michael StaehlerMSMichael Staehler
- Cora N. SternbergCSCora N. Sternberg
- Christian G. StiefCSChristian G. Stief
- 1 February 2012
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 61 (2) , 307-316
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- GlaxoSmithKline
This publication has 51 references indexed in Scilit:
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapyInternational Immunopharmacology, 2011
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI: Journal of the National Cancer Institute, 2011
- Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced UltrasonographyClinical Cancer Research, 2010
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell CarcinomaJournal of Urology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008